Acceder Registro /

Jose Luis ALONSO ROMERO

Buscador

Li X, Zhang Y, Zhu C, Xu W, Hu X, Martinez DAS, Romero JLA, Yan M, Dai Y, Wang H. Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer. BMC Womens Health. 2024 Jan 13;24(1):38. doi: 10.1186/s12905-023-02871-6. PubMed PMID: 38218823; PubMed Central PMCID: PMC10787989.
AÑO: 2024
Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, Adamchuk H, Salgado M, Yardley DA, Berzoy O, Zamora-Aunon P, Chan D, Spera G, Xue C, Ferreira E, Badovinac Crnjevic T, Perez-Moreno PD, Lopez-Valverde V, Steinseifer J, Fernando TM, Moore HM, Fasching PA; coopERA Breast Cancer study group. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023 Sep;24(9):1029-1041. doi: 10.1016/S1470-2045(23)00268-1. PubMed PMID: 37657462.
AÑO: 2023; IF: 51.1
Rosado-Jimenez L, Mestre-Terkemani Y, Garcia-Aliaga A, Marin-Vera M, Macias-Cerrolaza JA, Sarabia-Meseguer MD, Garcia-Hernandez MR, Zafra-Poves M, Sanchez-Henarejos P, Ayala de la Pena F, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F. Variantes geneticas recurrentes y priorizacion de variantes de significado clinico desconocido asociadas al sindrome de cancer de mama y ovario hereditario en familias de la Region de Murcia. Adv Lab Med. 2023 Jul 10;4(3):288-297. doi: 10.1515/almed-2023-0032. eCollection 2023 Sep. Spanish. PubMed PMID: 38075173; PubMed Central PMCID: PMC10701495.
AÑO: 2023
Rosado-Jimenez L, Mestre-Terkemani Y, Garcia-Aliaga A, Marin-Vera M, Macias-Cerrolaza JA, Sarabia-Meseguer MD, Garcia-Hernandez MR, Zafra-Poves M, Sanchez-Henarejos P, Ayala de la Pena F, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F. Recurrent genetic variants and prioritization of variants of uncertain clinical significance associated with hereditary breast and ovarian cancer in families from the Region of Murcia. Adv Lab Med. 2023 Sep 22;4(3):279-287. doi: 10.1515/almed-2023-0103. eCollection 2023 Sep. PubMed PMID: 38075165; PubMed Central PMCID: PMC10701504.
AÑO: 2023
Aguado de la Rosa C, Cruz Castellanos P, Lazaro-Quintela M, Domine M, Vazquez Estevez S, Lopez-Vivanco G, Firvida Perez JL, Alonso Romero JL, Ferrera Delgado L, Garcia Giron C, Diz Tain P, Alvarez Alvarez R, Mut Sanchis P, Fernandez Canton I, Manrique Abos I, Martinez Aguillo M, Gomez-Aldaravi Gutierrez L, Ortega Granados AL, Alvarez Cabellos R, Garcia Sebastian A, Garcia Sifuentes LF, Reguart N. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study). Lung Cancer. 2022 Nov;173:83-93. doi: 10.1016/j.lungcan.2022.09.010. Epub 2022 Sep 19. PubMed PMID: 36162227.
AÑO: 2022; IF: 5.3

Instituto de Investigación Sanitaria Acreditado

ISCII

Fondo Social Europeo "El FSE Invierte en tu futuro"

Fondo Social Europeo

Sello de Calidad Europeo "HR Excellence in Research"

HRS4R